Physician

Michael Thomas Caglia, M.D.

According to 2025 Medicare claims, Michael Caglia, M.D. (NPI: 1568789550) practices dermatology in the Midland, TX market, with the plurality of this provider's patient population coming from Midland, TX. This provider's primary affiliated billing organization is BASIN DERMATOLOGY (NPI: 1063003754; TIN: 853162122) and primary practice location at 79703-4822.

Caglia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 702 traditional Medicare patients, billed 6,817 HCPCS/CPT codes, and received $465,172 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 528 prescription claims across 191 beneficiaries totaling $584,120 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 90 records totaling $2,104. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $54,852 to $465,172. Similarly, Part D prescription costs have moved sharply higher in recent years, from $90,328 to $584,120. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$249K$498K2016 Medicare payment: $54,852 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $118,568 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $119,190 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $91,356 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $83,029 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $125,350 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $497,569 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $392,191 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $465,172 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
20163471,668$54,852
20176785,095$118,568
20186015,733$119,190
20194573,891$91,356
20204022,754$83,029
20215154,360$125,350
20226146,803$497,569
20236785,650$392,191
20247026,817$465,172

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$292K$584K2015 Drug cost: $90,328 (USD; Tot_Drug_Cst)2016 Drug cost: $80,522 (USD; Tot_Drug_Cst)2017 Drug cost: $58,136 (USD; Tot_Drug_Cst)2018 Drug cost: $61,576 (USD; Tot_Drug_Cst)2019 Drug cost: $69,876 (USD; Tot_Drug_Cst)2020 Drug cost: $152,090 (USD; Tot_Drug_Cst)2021 Drug cost: $344,926 (USD; Tot_Drug_Cst)2022 Drug cost: $526,913 (USD; Tot_Drug_Cst)2023 Drug cost: $447,440 (USD; Tot_Drug_Cst)2024 Drug cost: $584,120 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201553215$90,328
2016112279$80,522
2017208505$58,136
2018219541$61,576
2019180461$69,876
2020210620$152,090
2021314870$344,926
2022230682$526,913
2023176433$447,440
2024191528$584,120

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths241300$71
99203New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more163163$63
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more488921$58
17000Destruction of precancer skin growth, 1 growth315419$33
17003Destruction of precancer skin growth, 2-14 growths2441,241$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Humira(Cf) PenAdalimumab14392$149,832
Taltz SyringeIxekizumab11308$88,463
FluorouracilFluorouracil351,088$2,765
CiclopiroxCiclopirox Olamine391,160$1,727
TacrolimusTacrolimus14395$1,152

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.90$2,104ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Michael Thomas Caglia, M.D.?

Tedicare shows public-source Medicare data for Michael Thomas Caglia, M.D. (NPI 1568789550), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Thomas Caglia, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Thomas Caglia, M.D.?

Michael Thomas Caglia, M.D. is linked to BASIN DERMATOLOGY (billing NPI 1063003754) in the available physician profile data.

Does Michael Thomas Caglia, M.D. have Open Payments data?

Michael Thomas Caglia, M.D. has 90 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.